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Abstract
Objectives—Our aim was to retrospectively compare clinical data and characteristics of 
removed lesions of the cohort of patients undergoing therapeutical surgery for their tuberculosis.
Design and methods—Demographic and epidemiological details, clinical data, data on the 
surgery performed, macroscopic characteristics of the TB lesions removed, and outcome were 
recorded retrospectively from the 137 patients who underwent therapeutical surgery for their TB in 
Tbilisi, Georgia during 2014 and 2015.
Results—Men represented 70% of the included patients, presented more comorbidities and 
underwent operation earlier in terms of days between diagnostic and surgery. Women underwent 
operation at younger ages, and in MDR/XDR-TB cases, showed higher percentages of sputum 
conversion at >2 months and of fresh necrosis in the surgical specimens, suggesting a worse 
evolution. Half of cases were MDR/XDR-TB cases. In spite of being considered microbiologically 
cured according to WHO, a non despricable percentage of cases showed viable bacilli in the 
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surgical specimen. Even if no causality could be statistically demonstrated, differences could be 
encountered according to gender and drug susceptibility of the responsible strains.
Conclusions—According to our results, host factors such as gender, type of necrosis found in 
the lesions, size of lesions and presence of viable bacilli in the surgical specimen, should be 
included in future studies on therapeutical surgery of TB. As most of studies are done in MDR/
XDR-TB, more data on DS-TB operated cases are needed. Our results also highlight that, in spite 
of achieving the microbiologically cured status, sterilization might not occur, and thus new 
biomarkers and new methods to evaluate the healing process of TB patients are urgently needed 
and radiological assays should be taken into account.
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1. Introduction
According to the World Health Organization (WHO), Georgia has a high incidence of 
tuberculosis (TB) cases (116/100.000 habitants), with a high Multi-Drug Resistant TB 
(MDR-TB) burden (51% of all declared cases in 2015).1 In countries with high incidences, 
therapeutical surgery is still a good option to cope with TB complications and sequelae, as 
well as to reduce the bacilli burden2; and might be essential as an adjuvant to the appropriate 
chemotherapy in the MDR-TB cases.3 In this manuscript, we present a study that aimed to 
retrospectively compare clinical data and characteristics of removed TB lesions of a cohort 
of patients undergoing therapeutical surgery for their TB, in the National Center for 
Tuberculosis and Lung Diseases (NCTLD, Tblisi, Georgia).
2. Materials and methods
2.1. Design
The project was reviewed and approved by the Ethics Committee IRB00007705 NCTLD 
Georgia #1, IORG0006411 (Tbilisi, Georgia) and the Ethics Committee of Germans Trias i 
Pujol Hospital (Badalona, Catalonia, Spain) to ensure compliance with all current national 
and European laws on clinical studies. The study was registered at the clinicaltrials.gov 
database with the identifier NCT02715271. The results presented here were extracted from a 
retrospective cohort including all patients operated per clinical routine at the NCTLD.
2.2. Data
Data were recorded retrospectively and anonymously from the 2014 and 2015 surgical 
notebooks in a Spreadsheet created ad-hoc, including different categories on both the 
patients and the lesions’ characteristics. WHO definitions were used whenever possible.4 
Table 1 includes all data categories recorded, definitions and possible answers. Graph Pad 
Prism 6 software (La Jolla, CA, USA) was used to draw the figures. Statistical analysis was 
done using the independent 2 samples t-test to compare continuous variables. The 
associations with other categorical variables were tested with the Chi-square test or Fisher 
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exact test. All tests were two-tailed, and p-values less than 0.05 were considered statistically 
significant.
3. Results
3.1. Demographic and epidemiological features
A total of 137 patients underwent therapeutical surgery for their TB at the NCTLD during 
the years 2014 and 2015, 96 males (69.8%) and 41 females (30.8%). Men were older 
(median age = 43.5 years old) than women (28 years old). 25% of men had comorbidities: 
Hepatitis C Virus Infection (n = 15), Diabetes mellitus (n = 5), HCV and Diabetes (n = 3), 
and HCV plus HIV infection (n = 1). A total of 49 patients were smokers, 48 on a daily or 
mostly daily basis; representing a 48.9% and 2.4% of total male and female populations, 
respectively. The majority of women (92.6%) declared never drinking alcohol. The alcohol 
intake in men increased with age. While men declaring themselves abstemious (13.5%) had 
a median age of 26 years old, those declaring drinking on less than monthly (33.3%), 
monthy (52%) or weekly basis (8.3%) had a higher median age (45.6 years old). No 
statistically significant differences were encountered between DS-TB and MDR/XDR-TB 
groups.
3.2. TB data
The 92.7% of total cases recorded were pulmonary TB exclusively (127 patients), while in 
7.3% (10 patients) pleura involvement (as empyema) was found (being more frequent in 
males, not statistically significant). Pleura involvement was present in the 80% of MDR/
XDR-TB cases.
Approximately the half of the patients included were DS-TB (56.9%), and the other half, 
MDR or XDR (40.1%). Mono resistance was rare. Table 2 shows the number of cases for 
each category, as well as the number and percentage according to gender. The percentage of 
men and women were very similar regardless of the drug-sensitivity of the strains involved.
The chest X-ray assay (previous to surgery) showed the presence of a single lesion (only 
cavities and tuberculomas considered) for most of the patients (76%), while 19.2% showed 2 
lesions, and 4.8% up to three.
Most patients undergoing surgery had been considered bacteriology cured according to 
WHO’s definitions (96.3%). No statistically significant differences according to gender or 
drug susceptibility were found in the non microbiologically cured group of patients.
Figure 1 shows the results of time to culture’s negativization, in totals and stratified by 
gender and by the drug-sensitivity of the strains. As women included in this cohort were 
younger (28 vs 43.5 years old), we stratified the results by dividing the male cases in ≤43 
and >43 years old, to see if the gender itself could be an influence free from the age input. 
Differences were encountered between females and males of ≤43 years old, being 
statistically significant for DS-TB cases (p ≤ 0.0001). A high percentage of patients 
negativized the culture in ≤2 months (51.8%), especially if they were women or younger 
(median age of 33). The culture was always negative in a non despricable 31.3% of the 
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cases; and up to 40.6% of male cases when stratified by gender. Patients with culture 
negative at ≤2 months were younger than those in whom it had always been negative 
(median age of 33 vs 43 years old, respectively; p < 0.0001). When stratified by gender, this 
difference was only seen in males (median age: 37 vs 47 years old; p = 0.022); but the 
overall percentage of negative cultures in females was significantly lower. Statistically 
significant differences in terms of negativization of culture were encountered between DS-
TB and MDR/XDR-TB, both in total (p ≤ 0.0001) and when stratifying the results by age 
and gender (males ≤43, p = 0.0009; males >43, p = 0.0007; and females, p = 0.0169).
Nearly half of DS-TB cases negativized the culture at ≤2 M (47.4%), while in MDR/XDR-
TB cases, the proportion of patients with negative results at >2 M (29.0%) were increased 
but due to a decrease of always negative results (a 44.8% in DS-TB vs a 12.7% in MDR/
XDR-TB). Males and females were different, both in DS and MDR/XDR-TB cases, even if 
these differences were statistically significant only in DS-TB (p ≤ 0.0001). Negative cultures 
were more frequent in MDR/XDR-TB cases, especially if women or males >43 years old.
3.3. Surgery
The main indication for surgery was the presence of lesions (cavities and tuberculomas or 
empyemas) in the chest X-ray assays (73.7%), both in DS (65.3%) and MDR/XDR-TB 
(85.4%), in spite of a good treatment adherence. In case of MDR/XDR TB, patients had had 
a sputum conversion but high risk of failure or relapse according to WHO’s 
recommendations.5 The other indications were those cases not microbiologically cured 
(2.9%) and a miscellania that we called the “others” group (23.3%) and which included 
severe complications of the TB. This group was significantly larger for males (31.2%) than 
for females (4.8%), something expected as men undergoing surgery wexre older and had 
comorbidities. Surgery for complications of TB was more frequent in DS-TB cases (32.0% 
vs a 12.7% in MDR/XDR-TB; (p = 0.03)).
Men underwent surgery earlier compared to women, according to days between diagnosis 
and surgery date (208.5 and 263 days, respectively; p = 0.0037). In DS-TB cases, there was 
a remarkable increase in days between diagnosis and surgery date in womens’ cases vs 
mens’ (225.5 vs 81.5; p = 0.0002). Statistically significant differences were found between 
DS-TB and MDR/XDR-TB, both in total and when stratifying by gender. Table 3 shows all 
these results.
No statistically significant differences were encountered between DS and MDR/XDR-TB 
according to age, neither in total nor stratified by gender; even if MDR/XDR-TB operated 
patients tended to be younger than DS-TB: 34 (28–48) vs 43 years old (26.75–50.25).
Differences between DS and MDR/XDR-TB were found in terms of history of previous 
treatment (p = 0.0053). While relapse patients were more frequent among DS-TB cases 
(26.47% vs 3.77% for MDR/XDR-TB), more operated MDR/XDR-TB cases were new 
(64.15% vs 55.88% for DS-TB), had a history of previous treatment (26.41% vs 16.18% for 
DS-TB), or were under treatment after lost follow-up (5.66% vs 1.47% for DS-TB).
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Segmentectomy was the most frequent surgical procedure (56.9%), regardless of the gender 
of the patients, followed by lobectomy (30.%), pleural surgery (9.49%) and pulmonectomy 
(2.9%, which was performed in more MDR/XDR-patients than DS-TB: n = 3 vs n = 1).
In the majority of cases, only one lesion was removed (69.3%; vs n = 2 (17.5%), n = 3 
(3.6%) and pleura (9.4%)). In the resected lung tissue, in addition to the cavity or 
tuberculoma, there could be conglomerates foci, a single foci, areas of fibrosis, bulls, or 
bronchiectasis. No statistically significant differences were encountered on number of 
operated lesions when stratifying the results by gender, age, or drug sensitivity.
Only 6 patients suffered post-surgery complications, 5 of them being males of a median age 
of 41 years old. Haemorragia was the most frequent complication (n = 3). Other 
complications were pneumonia plus acute respiratory failure (n = 1), bronchopleural fístula 
(n = 1) and delayed unfolding of the operated lung (n = 1). Half of these patients (n = 3) 
were new patients and half (n = 3) were relapsed patients, having undergone treatment after 
failure. Half of the cases were DS-TB, and the other half, MDR (n = 2) or XDR-TB (n = 1, 
the female case).
3.4. TB lesions
Median size for all lesions was 2.4 cm (25%–75%: 2–2.8). No statistically significant 
differences in terms of lesions’ size were encountered, neither according to gender, patients’ 
age, type of necrosis (fresh, dry, both) or drug-sensitivity.
Despite the fact that out of the 137 patients 132 (96.3%) were WHO cured patients, in 123 
(93.1%) there was presence of necrosis in the lesion. Necrosis was macroscopically 
considered fresh in 71.5% of cases, dry in 6.5%, and both fresh and dry in 21.9%. Figure 2 
shows these results according to gender and sensitivity to TB drugs. Results showed 
statistically significant differences due to drug sensitivity in all cases but men of ≤43 years 
old (total, p = 0.0136; >43 males, p = 0.0418); females, p = 0.0412). Men of ≤43 years had 
lesions with a higher percentage of fresh necrosis when compared to women in DS-TB cases 
(81.8% vs 58.3%, p = 0.05) and less in MDR/XDR-cases (65% vs 86.6%, p = 0.023). Men 
of ≤43 years old had a higher percentage of fresh necrosis in lesions when compared to 
those of >43 in DS-TB cases (81.8% vs 72.7%, p = 0.014); and slightly less in MDR/XDR-
TB (p = 0.0106) Figure 3.
Patients being considered bacteriology non cured according to WHO, presented a higher 
percentage of fresh necrosis (60%), even if the n of this group (n = 5) was too small to 
extract conclusions.
Fibrosis/cirrhosis was found in the 89% of lesions, with a majority of cases being fibrotic 
(98.3%).
Table 4 reports the positive results obtained for AFB stain and culture on samples from 
surgical specimens, among those patients operated for presence of lesions in X-Ray, with 
cavities or tuberculomas, and considered bacteriologically cured according to WHO’s 
definitions. In 19 patients the microbiological study of surgical samples could not be done, 
either because sampling is not done during surgery due to surgical procedures (10 patients 
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with empyema, 3 with spontaneous pneumothorax, 1 with thoracoplasty), or for technical 
reasons (n = 5). Even if any statistical analysis is difficult to be performed and interpreted 
because of the small numbers obtained, a tendency toward higher percentage of positive 
culture in fresh necrosis vs both fresh and dry necrosis and in those patients always having 
negative sputum cultures can be seen.
3.5. Outcomes
Statistically significant differences were encountered between outcomes of DS-TB when 
compared to those obtained for MDR/XDR-TB (p < 0.0001). While the percentage of cured 
patients was similar (30.8% for the DS-TB and 24.5% for MDR/XDR-TB) as well as those 
not evaluated (1.4% vs 1.8%); the categories lost to follow-up (7.3% vs 16.9%), treatment 
completed (47.0% vs 1.8%) and outcome still not known (8.8 vs 35.8) showed very different 
values. For the patients with outcome still not known, they are still on treatment. Moreover, 
1.8% and 0% of failed treatment were recorded for MDR/XDR-TB and DS-TB, respectively. 
No statistically significant differences were encountered when stratifying the results by age 
or gender.
4. Discussion
Since the first recorded operation for TB, in 1726, therapeutical surgery was frequent and 
often essential for TB treatment, until the appearance of the chemotherapy in mid 20th 
century, and then was progressively abandoned. Nowadays, therapeutical surgery for TB is 
restricted to high TB burden countries, mostly to treat severe complications (as 
haemoptysis)6 or sequelae (as important fibrosis),7 especially if available chemotherapy 
options are limited (as in MDR/XDR cases),2,5,8 and with a good overall cure rate.2,9,10
As in other published studies,8,10–12 men was more frequent in our cohort. Men undergoing 
surgery were older than women, something understandable if we take into account that older 
men in our series had more comorbidities and toxic habits, more pleural involvement 
(secondary to the pulmonary disease), and more complications. The highest percentage of 
complications could also explain why men received surgery earlier compared to women 
(especially in the DS-TB cases), according to days between diagnosis and surgery date.
In our study, gender also seems to play a role in active TB and its course, as differences were 
still encountered when stratifying male cases by age and comparing female results with 
those for males under <43. Women underwent surgery at younger ages, and in MDR/XDR-
TB cases, showed higher percentages of sputum conversion at >2 months and of fresh 
necrosis in the surgical specimens. This could mean that even if overall men suffer more TB, 
the TB course tends to be worse in women, especially if MDR/XDR. Previous literature has 
described higher rates of progression to disease for females during reproductive years.13 
Even if this were exclusively described for progression to disease and did not explore a 
worse evolution or progression within the disease state, we hypothesize that reproductive age 
might play a role, as women included in our study had a median age of 28 years old. The sex 
bias has been long debated in tuberculosis field, and even if sociocultural (access to 
healthcare) and behaviour (as smoking) factors have been demonstrated to have a role in it, 
there is increasing proof that biological factors (such as sex steroid hormones or variations at 
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the TLR8 gene) might also have an important influence.14,15 Our results show no statistical 
cause-effect relationship between gender and all the other features we recorded, but as 
differences are still encountered, we do think this might be due to the n included in our 
cohort (n = 137) is considerably high, but still low to verify the causality between factors. As 
cohorts of surgically treated TB patients are relatively small, we would like to encourage 
other scientists to use the same categories we used here, in order to be able to reproduce and 
even sum up the results obtained.
Our results come to be added to those of previous studies showing the need of therapeutical 
surgery for MDR/XDR-TB cases, which in our cohort represented nearly half of the patients 
included.5,7,8,16 As expected, these cases negativized the sputum culture later than 2 months, 
and these results were statistically significant when compared to DS-TB cases. Patients with 
MDR/XDR-TB usually have either thick-walled cavitary lesions or with a destroyed lobe or 
lung that contains a substantial amount of bacilli, making it difficult for penetration of 
antibiotics.17,18 So, pulmonary cavities harbor millions of resistant organisms and the 
infection in these locations cannot be controlled by the host-specific immunity and, 
consequently, the surgical removal of these cavities may permit cure.19 Our data supports 
what led to Kurbatova et al. to propose culture conversion status at 6 months as a better 
correlator of treatment success.20 In 22.2% of these cases, surgical specimens were cultured 
and a positive result was obtained; a lower percentage than in a previous study conducted in 
the same center,21 but still high (22.2%).
More than half of the operated cases were DS-TB cases, in spite of that therapeutical surgery 
has been lately considered or recommended only for MDR/XDR-TB5; the main indication 
for surgery (65.38%) being the persistence of lesions in X-ray in spite of good adherence to 
treatment. There are many reasons confirming the legitimacy of surgical treatment of 
patients with pulmonary DS-TB, including a high risk of relapse, the presence of a localized 
lesion, the absence of any radiological and/or bacteriological improvements during the initial 
three to four months of chemotherapy, the irreversible morphological changes of the lungs 
and other respiratory organs due to the development of the fibrotic tissues during the 
progress of TB over the long term, or tuberculoma’s size of more than three centimetres.5 In 
countries of the former Soviet Union with a high prevalence of TB, there is a 
characteristically late referral of patients with tuberculosis (all forms) for medical attention. 
This results in a large number of patients with very advanced, extensive cavernous forms of 
a DS-TB, with strongly expressed irreversible morphological changes in the lungs, which 
poorly answer to medical anti-tuberculosis treatment, and therefore relatively more prone to 
surgical treatment than in the developed countries of Western Europe and America. 
Moreover, National TB guidelines of many countries of the former USSR include the 
persistence of cavitary lesions in X-Ray as one of the main indications for surgical treatment 
of DS-TB.22,23 Our results on the presence of necrosis (87.1%) and microbiologically 
persistence of alive bacilli (14%) in surgical specimens of DS-TB, as well as the proportion 
of relapse patients (26.47% for DS-TB vs 3.77% for MDR-TB) point to the feasibility and 
need surgery for indicated cases among patients with DS-TB.
It is difficult to compare these results to other studies, as most literature refers only to 
therapeutical efficacy of surgery in MDR/XDR-TB cases, and published data on DS-TB are 
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scarce.2,9,11 Our results could be partly explained by the high percentage of cases in which 
fresh necrosis was found in DS-TB, indicating a poor resolving evolution. To our 
knowledge, this is the first attempt to classify operated lesions during the last years. The 
classification between proliferative and exudative lesions (with dry and fresh necrosis, 
respectively), was done years ago describing the coexistence of several type of lesions in 
time, some tending to fibrosis and calcification (thus with more positive outcomes) and 
others with a higher exudative component, tending to liquefaction and usually related to a 
higher bacillary load.24 In our study, we divided the removed lesions into the presence of dry 
(considered as positive) or fresh necrosis (considered as negative), or the presence of both 
(as an intermediate phase). Even if most operated lesions showed fresh necrosis and this 
made it difficult to establish any statistically significant analysis, results showed differences 
according to gender, with a remarkable high proportion of presence of fresh necrosis in 
MDR/XDR-TB female cases, supporting the idea that women’s lesions might evolve worse 
under certain conditions. Despite the fact that almost all patients with MDR-TB and XDR-
TB have been treated for a long time (≥1 year) with second-line antitubercular drugs, 
MDR/XDR patients still have cavities; and in the absolute majority of them (94.44%), 
necrosis was detected in operating specimens (most of them of the fresh type). AFB stain 
and culture were found positive (in a 65.96% and 23.4%, respectively) in surgical specimens 
of those MDR/XDR-TB patients considered microbiologically cured, had cavities or 
tuberculomas and still had lesions in their X-ray assays. These results are similar to those 
previously published in the literature,8 but still frightening.
Presence of bacilli was found in surgical specimens in an important percentage of total 
cases, which was higher in MDR/XDR-TB cases, older patients and female patients, and in 
the presence of fresh necrosis. Moreover, from the 98% of DS-TB cases presenting cavities 
or tuberculomas and considered bacteriology cured according to WHO definitions, a non 
despricable 56% presented AFB positive at samples from the surgical specimens. Even if a 
positive AFB stain in a biological sample does not imply the presence of viable bacilli, up to 
14% of those cases considered bacteriologically cured were culture positive, including 2 
cases in which the AFB stain was negative. For us, this is the most important finding in our 
study, and poses doubts regarding the clearance effect of anti-TB drugs. During prolonged 
chemotherapy and decrease of bacterial load, a part of the microbial population remains in 
the host’s organism in the state of persistence, and as proposed by some authors, 
transformated to L-forms or small-grained forms, characterized with low virulence but 
proven capacity for reversion and previous virulence.25–27 The only validated biomarker 
now available to evaluate the curation of a patient, is to achieve a negative culture along a 
positive clinical evolution in a patient with a bacteriologically confirmed TB at the 
beginning of the treatment.4 And yet, our results in DS-TB which followed treatment 
correctly, proved that no sterilization was achieved. In our opinion, our results support the 
idea that the correlators used are not reflecting what is happening in situ, and therefore new 
biomarkers are urgently needed. During the last years, different genetic profiles and other 
biomarkers of TB disease have been described in peripheral blood, suggesting that they 
could be used to establish the key of future therapeutic approaches.28–32 As results might be 
different if measured in situ, surgical specimens might be a valuable tool to validate them.
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In conclusion, we would like to encourage other scientists to use our categories in their 
studies conducted with therapeutical surgery, and to publish their results on DS-TB operated 
cases. Moreover, our results highlight that, in spite of achieving the microbiologically cured 
status, sterilization might not occur. This suggests that new studies to search biomarkers able 
to correlate with the in situ disease are urgently needed, and that evolution of radiological 
assays should be taken into account, as they are essential. Altogether, this information will 
help us better understand the reality of TB and will foster the development of new 
appropriate and tailored therapeutic options.
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Figure 1. 
Time in sputum culture conversion.
Time to sputum culture conversion (always negative, less than 2 months (≤2 months) and 
more than 2 months (>2 months)) is represented in percentages, for DS-TB and MDR/XDR-
TB cases. Total values and results stratified by gender (males (of more or less than 43 years 
old) and females) are graphically represented.
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Figure 2. 
Necrosis type found in lesions.
Percentages of presence of the different type of necrosis (fresh, dry and both) are 
represented for DS-TB and MDR/XDR-TB cases. Total values and results stratified by 
gender (males (of more or less than 43 years old) and females) are graphically represented.
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Figure 3. 
Types of necrosis in surgical specimens.
Macroscopic photographs of removed surgical specimens showing fresh necrosis (A), both 
fresh and dry necrosis (B) and dry necrosis (C).
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Table 1
Data recorded
Group Category Variables
Demographic and epidemiological 
data
Age (years old) In years old
Gender Male/Female
Smoking habit on daily or almost daily basis, weekly, monthly, less than 
monthly, never
Alcohol intake on daily or almost daily basis, weekly, monthly, less than 
monthly, never
General clinical data Presence of comorbidities Diabetes mellitus, HIV infection, immunosupression other 
than HIV-infection, renal failure, chronic obstructive 
pulmonary disease (COPD) previous to TB, Hepatitis C 
Virus infection, hepatic cirrosis, others
Clinical data regarding the TB history of previous treatment new patient, relapse patient: treatment after failure, 
treatment after loss to follow-up patient, other previously 
treated patient, unknown previous TB treatment
anatomical site of TB Pulmonary, extrapulmonary
drug-sensitivity Drug Sensitive (DS-TB), Rifampicin Resistant only, 
Monoresistance to any other drug other than rifampicin, 
polydrug resistance, MultiDrug Resistant (MDR), 
extradrug resistance (XDR)
date of diagnosis of the present TB 
episode
dd/mm/yy
date of treatment initiation dd/mm/yy
number of lesions found in the chest X-
ray assay
n
bacteriology cured or not at the time of 
surgery according to WHO’s guidelines
Yes/No
time in negativization of culture Recorded in months, and analyzed as always negative, 
negative at ≤2 months (M) or negative at >2 M
time from TB diagnosis and surgery In days
Data regarding the surgery performed main indication for surgery Still lesions in X-ray assays, Clinically not cured, 
Microbiologically not cured, Others (spontaneous 
pneumothorax, pulmonary haemorrhage, pleural 
empiema)
number of operated lesions n
type of surgery performed segmentectomy (for lesion resection or removing lung 
segment), lobectomy (for lung resection or removing lung 
lobe), Pulmonectomy (for removal of the whole lung)
date of surgery dd/mm/yy
post-surgery complications Open answer
Data on macroscopical characteristics 
of the TB lesions removed (surgical 
specimens)
lesion size in cm, considering the maximum lenght
type of lesion operated tuberculoma, cavitation
presence of necrosis no necrosis, necrosis: moderate growth of connective 
tissue, alternating with unmodified lung tissue, cirrosis: 
complete substitution of lung tissue by the connective 
tissue with damage of vessels and bronchies
type of necrosis fresh: necrosis macroscopically looking like of a liquid 
consistency, dry: necrosis macroscopically looking like of 
a dry consistency, both: coexistence of fresh and dry 
necrosis
Presence of Acid Fast Bacilli (AFB) Yes/No
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Group Category Variables
Positivity of culture of samples in solid 
medium (Lowenstein-Jensen) for 
M.tuberculosis
Yes/No
Outcome Official final outcome according to 
WHO definitions
Treatment completed, Treatment success, Cured, Lost of 
follow-up, Treatment failed, Still not known, Not 
evaluated, Death (if death, date of death in dd/mm/yy 
recorded)
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Table 3
Days between diagnosis and surgery date.
Drug-Resistance (WHO) Median (25% – 75%)
TOTAL Males Females
All patientsa 233 (100 – 252.5) 208.5 (50.5 – 344)b 263 (210 – 373.5)b
DS-TB 178.5 (38.25 – 258.75)d 81.5 (17.5 – 225.25)c,e 225.5 (192.5 – 275)c,f
MDR/XDR-TB 351 (233 – 455)d 308.5 (215.75 – 405.5)e 373 (266.5 – 654)f
MDR-TB 305.5 (232 – 399.75) 307 (225 – 400.5) 304 (237 – 511)
XDR-TB 532 (276 – 666) 454 (166 – 610) 533 (372.25 – 891.5)
Abbreviations: WHO: World Health Organization; DS-TB: Drug-Sensitive Tuberculosis; monoR: mono Resistant; MDR/XDR-TB: Multi Drug-
Resistant/Extensively Drug-Resistant Tuberculosis.
aAll patients include: mono resistant, rifampicin only resistant, DS-TB and MDR/XDR-TB patients.
bStatistically significant differences between males and females, p = 0.0037.
cStatistically significant differences between DS-TB Males and DS-TB females, p = 0.0002.
dStatistically significant differences between TOTAL DS-TB and TOTAL MDR/XDR-TB, p <0.0001.
eStatistically significant differences between DS-TB males and MDR/XDR-TB males, p <0.0001.
fStatistically significant differences between DS-TB females and MDR/XDR-TB females, p = 0.0005.
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